ArticleDiscover oncology2026
SOAT1 expression associates with prognosis, immune environment and biochemical indicators in glioma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeThis study aims to investigate the association between sterol O-acyltransferase 1 (SOAT1) expression and patient prognosis, immune environment, and biochemical indicators in glioma.
methodsWe analyzed SOAT1 expression, immune cell infiltration, and patient prognosis using glioma cohorts from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases. A retrospective cohort of 195 glioma patients who underwent surgical resection at our institution between January 2016 and December 2020 was also included. Immunohistochemical (IHC) assays were performed to evaluate the expression of SOAT1 and immune cell markers, and these results were correlated with clinical parameters and biochemical indices.
resultsSOAT1 expression in gliomas increased with tumor grade. High SOAT1 expression was associated with worse prognosis, and this association remained significant in multivariable Cox models. Immune infiltration analysis revealed a significant positive association between SOAT1 expression and multiple tumor-infiltrating immune cells, particularly monocytes-macrophages and neutrophils. Furthermore, patients with high SOAT1 expression exhibited elevated circulating neutrophils, neutrophil-to-lymphocyte ratio (NLR), (white blood cell-neutrophil)-to-lymphocyte ratio (dNLR) and systemic immune-inflammation index (SII), accompanied by decreased lymphocyte and monocyte counts. Additionally, high SOAT1 expression was associated with reduced serum sodium (Na⁺) and chloride (Cl⁻) levels, as well as increased levels of bilirubin.
conclusionSOAT1 expression is closely associated with glioma prognosis, immune cell infiltration, systemic inflammatory and biochemical indicators. These findings offer novel insights into the role of SOAT1 in glioma and its broader implications for systemic immune and biochemical alterations, providing a foundation for future research into potential therapeutic targets and prognostic biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.